DE69939689D1 - Caspase inhibitoren - Google Patents

Caspase inhibitoren

Info

Publication number
DE69939689D1
DE69939689D1 DE69939689T DE69939689T DE69939689D1 DE 69939689 D1 DE69939689 D1 DE 69939689D1 DE 69939689 T DE69939689 T DE 69939689T DE 69939689 T DE69939689 T DE 69939689T DE 69939689 D1 DE69939689 D1 DE 69939689D1
Authority
DE
Germany
Prior art keywords
caspase inhibitors
caspase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939689T
Other languages
English (en)
Inventor
Marion W Wannamaker
Guy W Bemis
Paul S Charifson
David J Lauffer
Michael D Mullican
Mark A Murcko
Keith P Wilson
James W Janetka
Robert J Davies
Anne-Laure Grillot
Zhan Shi
Cornelia J Forster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69939689D1 publication Critical patent/DE69939689D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
DE69939689T 1998-03-19 1999-03-19 Caspase inhibitoren Expired - Lifetime DE69939689D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7877098P 1998-03-19 1998-03-19
PCT/US1999/005919 WO1999047545A2 (en) 1998-03-19 1999-03-19 Inhibitors of caspases

Publications (1)

Publication Number Publication Date
DE69939689D1 true DE69939689D1 (de) 2008-11-20

Family

ID=22146109

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939689T Expired - Lifetime DE69939689D1 (de) 1998-03-19 1999-03-19 Caspase inhibitoren

Country Status (34)

Country Link
US (3) US6531474B1 (de)
EP (6) EP2261232A3 (de)
JP (3) JP4594520B2 (de)
KR (2) KR100928878B1 (de)
CN (1) CN1321129C (de)
AP (1) AP2000001919A0 (de)
AR (1) AR019011A1 (de)
AT (1) ATE410439T1 (de)
AU (1) AU769033B2 (de)
BG (1) BG104863A (de)
BR (2) BR9909660A (de)
CA (1) CA2324226C (de)
CZ (1) CZ302281B6 (de)
DE (1) DE69939689D1 (de)
DK (1) DK1064298T3 (de)
ES (1) ES2315010T3 (de)
GE (1) GEP20043163B (de)
HK (1) HK1035733A1 (de)
HU (1) HU227920B1 (de)
ID (1) ID27002A (de)
IL (3) IL138469A0 (de)
IS (1) IS5622A (de)
NO (1) NO331829B1 (de)
NZ (2) NZ506963A (de)
PL (1) PL204619B1 (de)
PT (1) PT1064298E (de)
RU (1) RU2274642C2 (de)
SI (1) SI1064298T1 (de)
SK (1) SK286736B6 (de)
TR (1) TR200103406T2 (de)
TW (1) TWI243828B (de)
UA (2) UA74133C2 (de)
WO (1) WO1999047545A2 (de)
ZA (1) ZA200004652B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1064298E (pt) * 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7157430B2 (en) 1998-10-22 2007-01-02 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/CED-3 family of cysteine proteases
US7326542B2 (en) 1998-12-02 2008-02-05 Princeton University Compositions and methods for regulating bacterial pathogenesis
US6720415B2 (en) 1998-12-02 2004-04-13 Princeton University Compositions and methods for regulating bacterial pathogenesis
CA2386411A1 (en) * 1999-10-13 2001-04-19 Merck Frosst Canada & Co. Nicotinyl aspartyl ketones as inhibitors of caspase-3
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6525024B1 (en) 2000-04-17 2003-02-25 Idun Pharmaceuticals, Inc. Inhibitors of the ICE/ced-3 family of cysteine proteases
JP2003532698A (ja) 2000-05-10 2003-11-05 プリンストン ユニバーシティ 細菌の増殖および病理発生を調節するための化合物ならびに方法
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
PE20020500A1 (es) * 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
WO2002070544A2 (en) * 2001-03-02 2002-09-12 Idun Pharmaceuticals, Inc. Methods, compositions and kits for preserving antigenicity
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
WO2003068242A1 (en) * 2002-02-11 2003-08-21 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
WO2003075853A2 (en) 2002-03-08 2003-09-18 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
FR2839309B1 (fr) 2002-05-03 2004-07-23 Aventis Pharma Sa Nouveaux derives de l'acide hexahydro-pyridazine-3- carboxylique, chimiotheques les contenant, leur utilisation comme medicaments, compositions pharmaceutiques les contenant et leurs procedes de preparation
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
AU2003263393A1 (en) * 2002-09-04 2004-03-29 Glenmark Pharmaceuticals Limited New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
ATE380185T1 (de) 2002-10-23 2007-12-15 Glenmark Pharmaceuticals Ltd Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
FR2846969A1 (fr) * 2002-11-08 2004-05-14 Salles Jean Pierre Nouveaux vecteurs moleculaires amphiphiles fluorocarbones a usage biomedical et medical
AU2003295041A1 (en) * 2002-11-20 2004-06-18 L'oreal Composition for hair care or eyelashes containing a pyrazol-carboxamide, its use for stimulating hair and eyelash growth and/or for preventing loss thereof
FR2847160A1 (fr) * 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
EP1620429B1 (de) 2003-04-11 2009-04-01 Glenmark Pharmaceuticals S.A. Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
AU2003902704A0 (en) * 2003-05-29 2003-06-19 Crc For Waste Management And Pollution Control Limited Of Unsw Process for producing a nanoscale zero-valent metal
CA2547670A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ice inhibitors
ES2320643T3 (es) * 2003-12-12 2009-05-27 Dr. Straetmans Chemische Produkte Gmbh Composiciones con acido anisico y gliceridos.
AU2011226946B2 (en) * 2004-02-27 2012-05-03 Vertex Pharmaceuticals Incoporated Caspase Inhibitors and Uses Thereof
CN1942466B (zh) * 2004-02-27 2011-02-23 沃泰克斯药物股份有限公司 天冬氨酸特异性半胱氨酸蛋白酶抑制剂及其用途
EP2270004A1 (de) 2004-02-27 2011-01-05 Vertex Pharmceuticals Incorporated Caspaseinhibitoren und ihre Verwendung
JP4898658B2 (ja) 2004-03-12 2012-03-21 バーテックス ファーマシューティカルズ インコーポレイテッド アスパラギン酸アセタールカスパーゼ阻害剤の製造のための方法および中間体
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2566362C (en) 2004-05-15 2013-09-10 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
WO2006017295A2 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
US7709524B2 (en) * 2004-09-17 2010-05-04 Biomas Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme
BRPI0516341A (pt) 2004-10-13 2008-09-02 Glenmark Pharmaceuticals Sa método para preparação de intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, método para a preparação de compostos intermediários de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida, n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzeno [b,d] furano-1-carboxamida, método para a sìntese de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida e seu sal sódico de n-(3,5-dicloropirid-4-il)-4-difluorometoxi-8-metanoss ulfonamido-dibenzo [b,d] furano-1-carboxamida
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
SI1831227T1 (sl) 2004-12-17 2013-09-30 Glenmark Pharmaceuticals S.A. Nove heterociklične spojine uporabne za zdravljenje vnetnih in alergijskih motenj
JP4673068B2 (ja) * 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
DE102005017116A1 (de) 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
NZ566022A (en) 2005-07-28 2011-04-29 Vertex Pharma Caspase inhibitor prodrugs
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP2043672A4 (de) * 2006-07-07 2009-10-21 Univ Leland Stanford Junior Selektive caspase-hemmer
JP2010510224A (ja) * 2006-11-17 2010-04-02 アボット・ラボラトリーズ ケモカイン受容体拮抗薬としてのアミノピロリジン類
US8618663B2 (en) 2007-09-20 2013-12-31 International Business Machines Corporation Patternable dielectric film structure with improved lithography and method of fabricating same
US8084862B2 (en) * 2007-09-20 2011-12-27 International Business Machines Corporation Interconnect structures with patternable low-k dielectrics and method of fabricating same
US7709370B2 (en) 2007-09-20 2010-05-04 International Business Machines Corporation Spin-on antireflective coating for integration of patternable dielectric materials and interconnect structures
WO2009124265A1 (en) * 2008-04-03 2009-10-08 The Board Of Trustees Of The Leland Stanford Junior University Probes for in vivo targeting of active cysteine proteases
GB2475799A (en) * 2008-05-27 2011-06-01 Imp Innovations Ltd Hypoxia inducing factor (hif) stabilising glasses
US20110152343A1 (en) * 2009-12-22 2011-06-23 Functional Genetics, Inc. Protease inhibitors and broad-spectrum antiviral
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
GB201011411D0 (en) 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
WO2012061786A1 (en) 2010-11-05 2012-05-10 Brandeis University Ice cleaved alpha-synuclein a biomarker
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
ES2699226T3 (es) 2011-10-14 2019-02-08 Bristol Myers Squibb Co Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa
CN103987696B (zh) 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
SG11201501036RA (en) 2012-08-23 2015-03-30 Alios Biopharma Inc Compounds for the treatment of paramoxyvirus viral infections
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
SI2906551T1 (en) 2012-10-12 2018-05-31 Bristol-Myers Squibb Company CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2978751B1 (de) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisochinoline mit substituierten azolen als faktor-xia-hemmern
NO2760821T3 (de) 2014-01-31 2018-03-10
HUE040226T2 (hu) 2014-01-31 2019-02-28 Bristol Myers Squibb Co Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6966996B2 (ja) * 2015-09-17 2021-11-17 シティ・オブ・ホープCity of Hope Ｐｃｎａ阻害剤
WO2018016547A1 (ja) * 2016-07-22 2018-01-25 キッセイ薬品工業株式会社 ピロリジン誘導体
CA3047836C (en) 2016-12-23 2024-02-06 Andrea Leblanc Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
EP4251140A1 (de) * 2020-11-25 2023-10-04 Lysosomal and Rare Disorders Research and Treatment Center, Inc. Hemmung des caspase-wegs als behandlung lysosomaler speicherkrankheiten

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2973111A (en) * 1958-02-11 1961-02-28 Dempster Brothers Inc Compaction bodies
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5874424A (en) 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US4465679A (en) 1983-01-31 1984-08-14 Usv Pharmaceutical Corporation 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof
IL72523A (en) 1983-08-12 1988-06-30 Takeda Chemical Industries Ltd 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them
US5055451A (en) 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5158936A (en) 1986-12-22 1992-10-27 Syntex (U.S.A.) Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
US5008245A (en) 1988-10-27 1991-04-16 University Of Kentucky Research Foundation Novel peptidyl carbamate inhibitors of the enzyme elastase
ZA905737B (en) 1989-07-26 1991-05-29 Merrell Dow Pharma Novel peptidase inhibitors
NZ235155A (en) 1989-09-11 1993-04-28 Merrell Dow Pharma Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
AU7775991A (en) 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
EP0503561B1 (de) 1991-03-15 1998-10-28 Hoechst Aktiengesellschaft Verfahren zur diastereoselektiven reduktiven Pinakol-Kupplung von homochiralen alpha-Aminoaldehyden
EP0519748B1 (de) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
US6348570B1 (en) 1991-08-16 2002-02-19 Merck & Co., Inc. Chromophore containing compounds and their use in determining interleukin-1β convertase activity
US5278061A (en) 1991-08-16 1994-01-11 Merck & Co., Inc. Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme
EP0533226A3 (en) 1991-08-16 1993-08-18 Merck & Co. Inc. Novel chromophore containing compounds
EP0533350B1 (de) 1991-08-16 1999-05-26 Merck & Co. Inc. DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert
HU220098B (hu) 1991-08-30 2001-10-28 Vertex Pharmaceuticals Incorporated Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
EP0541946B1 (de) 1991-10-07 1996-07-17 Hoechst Aktiengesellschaft Verfahren zur diastereoselektiven reduktiven Pinakol-Kupplung von homochiralen alpha-Aminoaldehyden
GB9123326D0 (en) 1991-11-04 1991-12-18 Sandoz Ltd Improvements in or relating to organic compounds
AU1339092A (en) 1991-12-13 1993-07-19 Corvas International, Inc. Reagents for automated synthesis of peptide analogs
EP0547699A1 (de) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidylderivate als Inhibitoren von Interleukin-1-Beta-konvertierenden Enzymen
WO1993014777A1 (en) 1992-01-31 1993-08-05 Merck & Co., Inc. PEPTIDYL DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
DE69320176T2 (de) 1992-02-21 1999-04-08 Merck & Co Inc Peptidylderivate und inhibitoren des interleukin-1-g(b)-konvertierenden enzyms
JPH08500242A (ja) 1992-06-24 1996-01-16 メルク エンド カンパニー インコーポレーテッド インターロイキン１β前駆体の転換酵素をコードするＤＮＡ
JP2602181B2 (ja) 1992-07-31 1997-04-23 ファイザー・インク． 消炎薬としてのペプチジル４−アミノ−２，２−ジフルオロ−３−オクソ−１，６−ヘキサン二酸誘導体
CA2109646C (en) 1992-11-24 2000-03-07 Gaston O. Daumy Para-nitroanilide peptides
EP0618223A3 (de) 1993-03-08 1996-06-12 Sandoz Ltd Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
TW494094B (en) 1993-04-29 2002-07-11 Vertex Pharma Peptide analogs as irreversible interleukin-1β protease inhibitors and pharmaceutical compositions comprising the same
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US5411985A (en) 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
DE69413167T2 (de) 1993-06-04 1999-05-06 Vertex Pharma Peptid-Phosphinyloxymethyl-Ketonen als Inhibitoren von Interleukin-1 beta-konvertierenden Enzymen
EP0711174A4 (de) 1993-06-24 1997-11-12 Gen Hospital Corp Gene für den programmierten zelltod und proteine
WO1995005192A1 (en) 1993-08-13 1995-02-23 Merck & Co., Inc. SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
ATE163639T1 (de) * 1993-11-11 1998-03-15 Basf Ag P-hydroxyanilinderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen oder schädlingen
US5486623A (en) 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
US5714484A (en) 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
HU224731B1 (en) 1994-03-31 2006-01-30 Vertex Pharma Pyrimidinyl derivatives as interleukin inhibitors and pharmaceutical compositions containing them
AU705321B2 (en) 1994-04-29 1999-05-20 Vertex Pharmaceuticals Incorporated Halomethyl amides as IL-1beta protease inhibitors
US5492824A (en) 1994-05-12 1996-02-20 Basf Ag Ice and ice-like compositions and methods of making same
US5552400A (en) 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5565430A (en) 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
GB2292149A (en) * 1994-08-09 1996-02-14 Ferring Res Ltd Peptide inhibitors of pro-interleukin-1beta converting enzyme
US5498616A (en) 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
CA2215211A1 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
JPH09165360A (ja) * 1995-03-31 1997-06-24 Takeda Chem Ind Ltd システインプロテアーゼ阻害剤
US5798442A (en) 1995-04-21 1998-08-25 Merck Frosst Canada, Inc. Peptidyl derivatives as inhibitors of pro-apoptotic cysteine proteinases
WO1997008174A1 (en) 1995-08-31 1997-03-06 Smithkline Beecham Corporation Interleukin converting enzyme and apoptosis
EP0851760A4 (de) 1995-08-31 1998-11-25 Smithkline Beecham Corp Interleukin umwandelndes enzym und apoptose
EP0761680A3 (de) 1995-09-12 1999-05-06 Ono Pharmaceutical Co., Ltd. Tetrazolverbindungen mit Interleukin-1beta-konvertierendes Enzym inhibierende Aktivität
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6136834A (en) * 1995-12-27 2000-10-24 Ono Pharmaceutical Co., Ltd. Tetrazole compounds and pharmaceutical agents containing such derivative
WO1998001133A1 (fr) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
WO1998004539A1 (fr) 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Derives heterocycliques oxygenes
CA2265853C (en) 1996-09-12 2010-08-03 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1.beta.-converting enzyme (ice)/ced-3 family inhibitors
AU739496B2 (en) 1996-09-12 2001-10-11 Idun Pharmaceuticals, Incorporated Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
JP3492703B2 (ja) * 1996-09-12 2004-02-03 アイドゥン ファーマシューティカルズ，インコーポレイテッド システインプロテアーゼのＩＣＥ／ｃｅｄ―３ファミリーの阻害剤としてのＣ―末端変性（Ｎ―置換）―２―インドリルジペプチド
US5869519A (en) * 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5968927A (en) * 1996-09-20 1999-10-19 Idun Pharmaceuticals, Inc. Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes
US6184244B1 (en) * 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
HUP9700816A3 (en) 1997-04-28 1999-06-28 Gyogyszerkutato Intezet 3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2307844C (en) * 1997-10-31 2006-08-08 Kimberly-Clark Worldwide, Inc. Creped nonwoven materials and liner
PT1064298E (pt) * 1998-03-19 2009-01-02 Vertex Pharma Inibidores de caspasas
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6242422B1 (en) * 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
EP2270004A1 (de) * 2004-02-27 2011-01-05 Vertex Pharmceuticals Incorporated Caspaseinhibitoren und ihre Verwendung
CN1980658A (zh) * 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂

Also Published As

Publication number Publication date
AU3098699A (en) 1999-10-11
BRPI9909660B1 (pt) 2018-09-18
IL138469A0 (en) 2001-10-31
HU227920B1 (en) 2012-06-28
ID27002A (id) 2001-02-22
UA96113C2 (en) 2011-10-10
KR20010042038A (ko) 2001-05-25
BR9909660A (pt) 2000-11-21
CZ20003409A3 (cs) 2001-01-17
CN1321129C (zh) 2007-06-13
PL343611A1 (en) 2001-08-27
CA2324226C (en) 2012-06-05
SK13822000A3 (sk) 2001-04-09
TWI243828B (en) 2005-11-21
BG104863A (en) 2001-04-30
HUP0103575A2 (hu) 2002-02-28
EP2011800A2 (de) 2009-01-07
EP2261235A3 (de) 2011-04-20
CA2324226A1 (en) 1999-09-23
NZ506963A (en) 2003-10-31
JP2010241822A (ja) 2010-10-28
US8691848B2 (en) 2014-04-08
EP2261234A2 (de) 2010-12-15
CZ302281B6 (cs) 2011-01-26
KR20080020703A (ko) 2008-03-05
EP2011800A3 (de) 2009-06-24
IS5622A (is) 2000-09-08
EP1064298B1 (de) 2008-10-08
JP4594520B2 (ja) 2010-12-08
NO331829B1 (no) 2012-04-16
EP1064298A2 (de) 2001-01-03
DK1064298T3 (da) 2009-01-19
JP2002506878A (ja) 2002-03-05
TR200103406T2 (tr) 2002-06-21
HUP0103575A3 (en) 2002-10-28
EP2261235A2 (de) 2010-12-15
US6531474B1 (en) 2003-03-11
SK286736B6 (sk) 2009-04-06
JP2006206600A (ja) 2006-08-10
WO1999047545A2 (en) 1999-09-23
EP2261233A2 (de) 2010-12-15
ES2315010T3 (es) 2009-03-16
GEP20043163B (en) 2004-01-26
KR100898094B1 (ko) 2009-05-18
NO20004546D0 (no) 2000-09-12
CN1323314A (zh) 2001-11-21
NZ528282A (en) 2005-05-27
EP2261232A3 (de) 2011-04-20
PL204619B1 (pl) 2010-01-29
US20030232986A1 (en) 2003-12-18
AU769033B2 (en) 2004-01-15
SI1064298T1 (sl) 2009-02-28
KR100928878B1 (ko) 2009-11-30
EP2261232A2 (de) 2010-12-15
AR019011A1 (es) 2001-12-26
BRPI9909660B8 (pt) 2021-05-25
RU2274642C2 (ru) 2006-04-20
HK1035733A1 (en) 2001-12-07
AP2000001919A0 (en) 2000-09-30
UA74133C2 (uk) 2005-11-15
ATE410439T1 (de) 2008-10-15
EP2261234A3 (de) 2011-04-20
NO20004546L (no) 2000-11-09
IL138469A (en) 2010-11-30
EP2261233A3 (de) 2011-04-20
IL206621A0 (en) 2010-12-30
US7358273B2 (en) 2008-04-15
WO1999047545A3 (en) 1999-11-25
ZA200004652B (en) 2002-04-24
US20090048226A1 (en) 2009-02-19
PT1064298E (pt) 2009-01-02

Similar Documents

Publication Publication Date Title
DE69939689D1 (de) Caspase inhibitoren
PT1114051E (pt) Inibidores de p38
DE59914158D1 (de) Metallocenmonohalogenide
ATE341990T1 (de) Sigmidoskop
DE59911453D1 (de) Aktivkohlefilter
DE69808145D1 (de) Tintenbehälternachfüllsystem
DE59912371D1 (de) Gleitschalungsfertiger
DE59901560D1 (de) Retrograder tibianagel
DE59902874D1 (de) Buchsenkontakt
NO990603D0 (no) HÕrkondisjoneringsblandinger
DE59907306D1 (de) Fadenchangierung
ID24221A (id) Tempat patrum
DE59911683D1 (de) Fahrzeugschliessanlage
DE69811890D1 (de) Einzellenkalorimeter
ATE262513T1 (de) Benzoylpyridazine
DE59913393D1 (de) Fadenchangierung
DE59908769D1 (de) N-arylsulfonyl-aminosäure-omega-amide
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE59903106D1 (de) Tripode-gleichlaufdrehgelenk
DE59901046D1 (de) Methylcyclotetradec-5-en-1-one
DE59908057D1 (de) Underdruckhandhabungseinrichung
DE69809804T2 (de) Notlaufgeländereifen
DE59807217D1 (de) Nadellager
DE1118098T1 (de) Mehrfachflussigelektrosprühschnittstelle
DE59808995D1 (de) Endomikroskopsystem

Legal Events

Date Code Title Description
8364 No opposition during term of opposition